Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Systemic lupus erythematosus is a nonspecific autoimmune disease of unknown cause. The clinico-biological manifestations and the progressive profile are variable. The objective of this study was to describe the epidemiological, diagnostic, therapeutic and progressive aspects of systemic lupus erythematosus at the Renaissance and National Reference university hospitals in N’Djamena
This was a cross-sectional and descriptive study running from January 1, 2019 to December 31, 2021 and which covered all the files of patients diagnosed with systemic lupus erythematosus according to the ACR (1997) or EULAR/ACR (2019) criteria).
In total, 13 patients were included. The hospital prevalence was 1.3%. The average age was 32 years with [14 and 68 years] and a sex ratio of 0.44. General signs were found in 11 patients (84.61%). This involved deterioration of general condition in 8 cases (61.5%), arterial hypertension in 2 patients (15.4%). There were polyarthralgia’s in 61.5% (n=8), 15.4% (n=2) generalized myalgias and 1 case of wrist arthritis (7.7%). Malar erythema represented 30.8% (n=4). Renal complications were present in 46.2% (n=6). This involved proteinuria greater than 500 mg/24 hours (46.2%) and hematuria in 15.4% (n=2). Renal function was disturbed in 5 patients (38.5%). The histology carried out after the renal biopsy in the 6 patients with renal damage revealed class I lupus nephropathy in 7.7% (n=1), class III lupus nephropathy in 15.4% (n= 2) and lupus nephropathy class IV in 23.1% (n=3). All patients were on hydroxychloroquine and corticosteroid therapy. Induction treatment in lupus nephropathy consisted of the administration of azathioprine in 38.5% (n=5). The dosage was 2 mg/kg/24 hours. The outcome at 6 months was unfavorable with the occurrence of 5 deaths in patients with lupus nephropathy. The causes of death were septic shock (15.4%), hypovolemic shock due to heavy hemoptysis (7.7%), massive pulmonary embolism (7.7%) and one undocumented case (7.7%). There were 5 cases of remission (38.5%), 2 cases of relapses (15.4%) and one patient lost to follow-up (7.7%).
Lupus is an underdiagnosed pathology in Chad. Its hospital prevalence is 1.3%. Its clinical expression is polymorphic and dominated by arthrocutaneous involvement. Renal complications are fatal for patients.
